[PDF][PDF] Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancer
S Johnston, J Pippen Jr, X Pivot… - Journal of Clinical …, 2009 - breastcancer.org.nz
Journal of Clinical Oncology, 2009•breastcancer.org.nz
Purpose Cross-talk between human epidermal growth factor receptors and hormone
receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the
effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor
receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor
letrozole as first-line treatment of hormone receptor (HR)–positive metastatic breast cancer
(MBC).
receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the
effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor
receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor
letrozole as first-line treatment of hormone receptor (HR)–positive metastatic breast cancer
(MBC).
Purpose
Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (HR)–positive metastatic breast cancer (MBC).
breastcancer.org.nz